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Abstract
Purpose of Review Cognitive impairment leading to disability is increasingly seen in people living with human immunodefi-
ciency virus (PLWH). Rehabilitation can alleviate the effects of cognitive impairment upon function. The aim of this paper is to
discuss the strategies that have been used in cognitive and neurologic rehabilitation in PLWH.
Recent Findings Studies examining pharmacological and non-pharmacological strategies were analysed. Medical management
of HIV and co-morbidities should be optimised. Non-pharmacological strategies, including nerve stimulation techniques,
exercise-based interventions, and paper and computer-based cognitive rehabilitation, have some evidence supporting their use
in PLWH either as stand-alone interventions or as part of a multidisciplinary approach.
Summary Both pharmacological and non-pharmacological rehabilitation strategies have been used with PLWH. More interven-
tion trials are needed to assess cognitive and neurological rehabilitation strategies and further evaluate their potential benefit in
PLWH.
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Introduction
HIV-associated neurocognitive disorder (HAND) was
characterised by severe cognitive dysfunction leading to de-
mentia and death in the pre-antiretroviral era [1]. The intro-
duction of combination antiretroviral therapy (cART) de-
creased the incidence of the most severe HAND cases [2–4].
It also transformed the management of HIV infection from the
symptomatic control of a life-limiting disease to the care of a
chronic condition that is associated with a close to normal
lifespan [5].
Whilst the most severe forms of HAND are now rare,
milder cognitive impairments persist amongst PLWH [3, 6,
7]. Recent study cohorts suggest that cART does not alter the
prevalence of cognitive impairment in PLWH [6, 8, 9].
Furthermore, new HIV-related neurological complications
have become apparent with the widespread use of cART.
Encephalopathy due to HIV discordance between plasma
and cerebrospinal fluid (CSF) [10–12] and CD8 encephalitis
[13] is rare but recognisable central nervous system (CNS)
presentations seen in PLWH on cART. It has also emerged
that some antiretrovirals, such as efavirenz, have direct CNS
toxicity [14, 15]. HIV infection is also associated with a higher
risk of cerebro- and cardiovascular disease, either by lifestyle,
direct viral or antiretroviral effects [16] (e.g. hyperlipidaemia
caused by protease inhibitor–based therapy). Cerebrovascular
disease is associated with an increased prevalence of neuro-
logical disability and cognitive difficulties. As the life expec-
tancy for PLWH increases due to improved medical manage-
ment, it has become apparent that some PLWH with neuro-
logical and cognitive impairments may survive for many years
following acute or ongoing neurological insults.
Rehabilitation strategies are needed to improve quality of
life, day to day functional performance and to mitigate further
cognitive impairment. Neurological rehabilitation can be de-
fined as a process that aims to optimise health, social func-
tioning and sense of well-being through restorative and
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compensatory strategies [17]. This definition highlights that
rehabilitation should be a personalised intervention. It is not a
process restricted to people who may recover, partially or
completely, but applies to all.
The London Taxi driver study [18•] showed that neuronal
volumes can be influenced by tasks, demonstrating the con-
cept of neuroplasticity following interventions. Neurological
rehabilitation strategies, particularly those involving multidis-
ciplinary teams (MDT), have been traditionally used in co-
horts of people with more static brain injuries, such as trau-
matic brain injury, stroke or post-hypoxic brain injury [19] but
also increasingly in chronic diseases such as multiple sclerosis
[20]. These teams include physicians and psychiatrists, reha-
bilitation nurses, physiotherapists, speech and language ther-
apists, occupational therapists and psychologists.
In this review, we discuss the strategies that have been used
in cognitive and neurologic rehabilitation in PLWH.
Methods
We reviewed outcomes data in our neuro-rehabilitation unit
for PLWH.
We used PubMed, Embase, CINAHL, and the Psychology
and Behavioural Sciences databases to search for the terms
‘HIV’, ‘cognitive’, and ‘neurological’ and ‘rehabilitation’.
We reviewed 892 abstracts and selected studies in English that
had a clear rehabilitation intervention and described the out-
comes in PLWH.
Results
Whilst many publications looked at cognitive and neurologi-
cal disability and rehabilitation techniques, the majority did
not describe the analysis of an intervention: most of these
studies were not randomised, had only small numbers of
PLWH and were pilot studies.
We have highlighted studies that demonstrate particular
rehabilitation strategies that best illustrate the changes experi-
enced by PLWH following the intervention.
Multidisciplinary Therapy Team Strategies—the
Example of Mildmay Hospital
The Mildmay hospital is an inpatient and day therapy unit in
London which is dedicated to the rehabilitation of people with
neurological disability caused by or associated with HIV infec-
tion. With the use of cART, it evolved from a palliative care unit
for people dyingwithHIV infection to a rehabilitation unit. In the
pre-cART era, the brain impairment unit gained experience of
delivering neurological and cognitive assessment and care to
PLWH admitted for long-term care. Those admitted were very
immunocompromised and had neuro-behavioural problems,
with severe cognitive impairment secondary to HIV-related neu-
rological disorders (e.g. HIV encephalopathy), opportunistic in-
fections (e.g. cerebral toxoplasmosis or progressive multifocal
leukoencephalopathy) or brain tumours. A combination of reha-
bilitation techniques and cART led to patients with HIV-related
brain pathology being discharged with better function rather than
dying within the unit [21•].
Currently, PLWH admitted toMildmayHospital have been
diagnosed with HAND or with cognitive and physical impair-
ments due to neurological opportunistic infections or other
HIV-related brain pathology. They tend to have been diag-
nosed late with HIV infection or have had poor adherence to
cART. PLWH are assessed by an MDT that includes an HIV
physician, psychiatrist, physiotherapist, occupational thera-
pist, dietitian, social worker, speech and language therapist
and psychologist, who design a personalised programme of
rehabilitation to meet individual needs and goals.
We measure change during rehabilitation with the
Functional Independence Measurement (FIM) and
Functional Assessment Measure (FAM) scales adapted for
use in the United Kingdom (UK) [22, 23]. These are the prin-
cipal outcome measure for the UK national database for spe-
cialist rehabilitation in patients with complex disabilities [24]
(the UK Rehabilitation Outcomes Collaborative (UKROC)).
The FAM was developed in the early 1990s for people with
traumatic brain injury and includes 12 items that focus on
cognitive and psychosocial function [23]. It is used in combi-
nation with the 18-item FIM at admission and discharge. The
outcomes can be viewed in the form of a ‘splat-plot’ that
change from admission to discharge by the differential area
covered, with higher scores indicating better function. An ex-
ample of the outcomes can be seen in Fig. 1 and Table 1.
An advantage of this multidisciplinary approach to rehabil-
itation and its evaluation is that it focuses on measuring func-
tional, more ecological outcomes, rather than neurocognitive
test scores, and may havemore validity to people’s daily lives.
‘Medical Maximisation’ Strategies with cART
Although it is now widely accepted that all PLWH regardless
of stage of disease should be commenced and maintained on
cART [25], this has not always been the case. Due to the
toxicities of older regimes, cART was mostly used to treat
patients with symptomatic immunosuppression.
Many PLWH benefited cognitively when started on
highly active cART, with a global improvement in cogni-
tive domains affected by the disease [8, 26, 27]. On the
other hand, there were occasional examples of cohorts that
improved cognitively by stopping cART, suggesting a tox-
icity effect of some medications [28]. Based on this evi-
dence, treatment guidelines suggested that all patients with
HIV-related cognitive impairment should be placed on
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Complexity (serial RCS-E scores)
RCS-E v12 score (mean) 11.2 11.4 11.1 11.3
% High/very high assessments 68.0% 64.6% 60.9% 65.5%
Functional gain (FIM + FAM scores)
% reported 61% 64% 25% 60%
Motor score on admission (mean) 90.7 87.9 67.3 88.7
Motor score on discharge (mean) 99.2 96.7 79.0 97.5
Motor gain during episode (mean) 8.5 8.9 11.7 8.8
Cognitive score on admission (mean) 70.9 72.8 46.3 71.0
Cognitive score on discharge (mean) 77.3 80.7 65.3 78.5
Cognitive gain during episode (mean) 6.5 7.9 19.0 7.5
FIM + FAM efficiency (median) 0.2 0.1 0.0 0.1
FIM + FAM efficiency (pop. mean) 0.2 0.2 0.4 0.2
Reduction in cost of ongoing care
% reported (optional) 34% 51% 75% 44%
Mean NPCNA cost/week on admission £1216 £706 £606 £894
Mean NPCNA cost/week on discharge £548 £392 £73 £413
Mean saving in cost/week £668 £314 £532 £481
NPCNA cost efficiency index (median) 18.4 1.5 4.0 3.8
NPCNA cost efficiency index (pop.median) 7.4 4.7 7.2 6.1
Fig. 1 Splat-plot of FIM + FAM
domain admission and discharge
scores in 2019. FIM, functional
independence measure; FAM,
functional assessment measure
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cART, even at a time when they were unable to make such
a recommendation for all patients [29].
Pharmacodynamics and pharmacokinetics of individual
ART medications within the CNS differ when compared with
the systemic circulation. This underpinned the hypothesis that
some drugs lack efficacy in the CNS due to a decreased drug
penetration in the CNS compartment and the concept of an
ARV regimen CNS Penetration-Effectiveness (CPE) score
(the higher the score, the better the CNS penetration) [30]. A
number of studies have used this ranking system to examine
whether regimes with higher CPE scores have an impact upon
PLWH’s cognition but the results have been inconsistent, with
both positive and negative results reported [31–34].
Another strategy was the addition of maraviroc to the re-
gimes of patients with cognitive impairment. Maraviroc has
an effect on neuro-inflammation and monocyte activity, and
was used as an adjunct in virologically suppressed patients,
with some success in small pilot studies [35, 36]. Other cART
optimisation strategies include a switch from regimes that
have been associated with poor neurocognitive performance,
particularly efavirenz. Neuropsychological symptoms, and in
some cases objective neuropsychological dysfunction, have
been noted as side effects of using efavirenz in cART regimes
[15], and switching from efavirenz-containing regimes has
been associated with improvedwell-being but not always cog-
nitive benefit in formal testing [37].
Recently, a differentially resistant virus in CSF and plasma
(HIV compartmentalisation) has been found in PLWH with
neurologically symptomatic disease. Although symptomatic
HIV CSF escape is rare [10, 11], modification of cART ac-
cording to the genotypes of both plasma and CSF compart-
ments may improve cognitive symptoms amongst these
patients.
‘Medical Maximisation’ Strategies—Management of
Co-Morbidities
There continues to be some debate about the aetiology of
cognitive difficulties in HIV infection and the extent to which
other medical problems that are affecting PLWH also com-
pound the effects of HAND [3].
Co-infections have been associated with neurocognitive
impairments, and therefore require effective management.
Hepatitis C infection is associated with neurocognitive impair-
ments in both mono-infected patients and in those co-infected
with HIV infection [38, 39]. There have been some studies
demonstrating some neurocognitive benefit in virological
clearance of hepatitis C with both interferon and direct acting
agents [40, 41].
Poorly controlled cardiovascular risk factors such as diabe-
tes or hypertension are associated with poorer cognitive out-
comes in PLWH [36–39]. Studies in improved management
of those diseases have shown mixed results in improving cog-
nition [42].
Many cohort studies show high levels of psychiatric disor-
ders in PLWH. Depression and anxiety can mask or resemble
symptoms of cognitive impairment. In addition, severe mental
health difficulties may affect performance in neurocognitive
tests and the ability of PLWH to perform day to day tasks.
There is some evidence that neurocognitive functions can be
improved by active treatment of depression with some antide-
pressants [43].
There has also been interest in the treatment of HAND by
the addition of other adjunctive medications to try to amelio-
rate the cytokine changes associated with HAND [44–47].
The effects in pilot studies have been variable, but usually
disappointing, showing very little real cognitive change.
Nerve Stimulation Techniques
A number of different nerve stimulation techniques have been
proposed as adjunctive methods as part of neuro-rehabilita-
tion. Techniques such as binaural beat therapy have been used
experimentally to treat anxiety and improve cognitive process-
ing. Similarly, vagal nerve stimulation has been examined as a
treatment for both refractory depression and epilepsy: some of
the patients treated in these studies had some improvements in
attention and memory recall. Neither of these techniques has
yet been used in PLWH.
However, transcranial direct current stimulation has been
trialled in PLWH. Electrodes are placed cutaneously over
parts of the scalp corresponding to neural networks, and are
thought to influence change in neuronal activity or neurotrans-
mitter release. This was tested in a driving simulation study,
combined with speed of processing cognitive remediation
therapy in a randomised 1:1 fashion between two groups of
15 unimpaired PLWH. Results suggested more cautious driv-
ing behaviour following active intervention. People in the
training group showed fewer lane deviations and a slower
average driving speed, in contrast to the control group who
showed an increase in driving deviations and average driving
speed [48].
A combination of techniques was tested further in a group
of 33 older (> 50 years) PLWH. The participants underwent
neuropsychological testing and training with combination
speed of processing cognitive remediation therapy, and were
then randomised to receive either real transcranial direct stim-
ulation (n = 17) or not (n = 16). The neuropsychological test-
ing after the intervention showed small-to-medium effects in
the executive and speed of processing measure. Medium-to-
large effects were observed for an executive/attention and oral
reading measure. There were small-to-medium and medium-
to-large effects for two speed of processing measures in the
opposite direction (i.e. the control group showed greater im-
provements). However, the only statistically significant effect
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was seen on the oral reading measure [49]. It is a technique
that needs further studies to examine it further as part of a
neuro-rehabilitation strategy.
Exercise-Based Interventions
Exercise- or physical activity–based interventions were used
to both improve cognitive abilities, or to prevent cognitive
decline in PLWH. There is already a body of data attesting
to the benefits of exercise on cognition in non-HIV popula-
tions [50, 51].
A small study randomised 11 PLWH who were not cogni-
tively impaired at baseline into either an exercise group (n = 5)
who completed a 16-week aerobic exercise programme train-
ing 3 times per week or a control non-exercise group (n = 6).
The results showed higher moderate physical activity corre-
lated with higher MOCA scores, but exercise training did not
induce significant improvements in cognitive function [52]. It
is important to note that adherence to the intervention was
only 60%.
Yoga as a strategy for cognitive improvement was tested in
18 adolescent PLWH at a rehabilitation centre in India. It was
a single-group study with a pre- and post-intervention assess-
ment of general health, immune parameters, quality of life and
cognitive functioning. All the participants were all given 1 h
of yoga daily for 6 months. The results demonstrated an im-
provement in general health of the participants. However, the
cognitive function analysis had mixed results with improved
psychomotor performance but worsened executive function-
ing [53]. This is a strategy which has seen some promising
results in the general older population and deserves to be stud-
ied further.
Paper-Based Cognitive Rehabilitation
A study from San Diego used Goal Management Training
(GMT) and metacognitive training as a strategy for improving
executive function difficulties, seen in people with HAND and
in people with substance use. GMT showed efficacy in im-
proving executive function difficulties in daily life.
Metacognition or ‘thinking about thinking’ is based on an
active awareness of cognitive functions and understanding
of cognitive difficulties, which is also often suboptimal in
those with HAND and those who use substances.
Ninety PLWH with a previous or current history of sub-
stance use and current executive function difficulties were
randomised 1:1:1 to either receive a single session of Goal
Management Training or a single session of both Goal
Management Training plus Metacognitive Training or to an
active control group, with 30 participants in each group [54].
The results suggest that a brief, single session of Goal
Management Training (GMT) protocol has some effect on
multitasking abilities.
An Italian study is an example of the combination of paper-
based and computerised cognitive–based exercises as a cog-
nitive rehabilitation strategy. Thirty-two PLWH (16 with and
16 without HAND) were randomised 1:1 to the intervention
(eight different exercises, lasting about 50 min in duration,
which were repeated 36 times over a 4-month period) or as a
control. Neurocognitive assessment was performed before,
and after the study in all participants, and six months after
the completion of the intervention for those in the interven-
tional arm. The intervention was directed at improving abili-
ties within four cognitive domains: attention, visual-verbal
memory and learning, executive functioning and working
memory, and metacognitive awareness. The intervention
group demonstrated improvements in five of eight cognitive
domains measured, including learning and memory,
abstraction/executive function, verbal fluency, attention, and
functional tasks, whereas those in the control group showed a
deterioration in those domains. When re-measured after
6 months, the intervention group had maintained improve-
ments in abstraction/executive functioning, attention/
working memory and functional tasks [55••]. This demon-
strates that patients can participate in a cognitive rehabilitation
protocol, make cognitive gains and maintain them, including
in functional tasks 6 months after completion of the
programme.
Computer-Based Strategies
Computerised neuropsychological assessments have be-
come increasingly common in recent years. There has been
particular interest in brief screens and their use in interven-
tion studies. This is because of the speed of execution and
decreased cost compared with traditional full neuropsycho-
logical assessments. They have been validated in several
disease areas including in PLWH with various degrees of
cognitive impairment. There has also been some interest in
using computerised cognitive rehabilitation programmes,
as these potentially have the advantage of being able to
be performed in the community without supervision. A
couple of studies have shown some potential advantages
and disadvantages of the approach.
In a partially randomised study of 30 PLWH and 30 HIV-
negative adults, those assigned to the intervention group were
asked to use SmartBrain (SmartBrain Technologies, 2013)
from their home computer for 24 weeks, initially for 10 min
and increasing weekly to a maximum of 30 min [56].
SmartBrain contains 14 game-like modules in the domains
of memory, attention, knowledge and executive functions.
Participants were tested with an extensive battery of
neurocognitive assessments before and after the intervention.
Primary results from this study revealed no significant effects
of SmartBrain on global cognitive outcomes, irrespective of
HIV serostatus. However, adherence to the intervention was
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poor with only 54% of participants able to use the programme
more than once. A post hoc analysis showed that the most
benefit was gained by those who undertook the intervention
most frequently.
In Uganda, 159 6 to 12-year-old HIV positive children
were randomised 1:1:1 to a group either receiving a
computerised rehabilitation programme using computer
games that was progressively more difficult, to a limited pro-
gramme that generated games of random degrees of difficulty,
or no computerised intervention, over a 2-month period [57••].
The computerised rehabilitation package was called Captain’s
Log (BrainTrain Corporation) programmed with games to im-
prove working memory, attention and visual–spatial analysis.
Planning and knowledge domains had significantly greater
gains at follow-up in the full intervention group when com-
pared with controls. Both intervention arms had significant
improvements on learning tests compared with controls.
This demonstrates that this could be a strategy for use in
resource-poor country situations.
Conclusion
Cognitive impairment is still prevalent in PLWH in the cART
era, and can lead to disability affecting activities of daily liv-
ing. Both pharmacological and non-pharmacological rehabil-
itation strategies are currently being increasingly used to min-
imise the effect of such impairments. Early studies suggest
promise in remediating some of the cognitive impairment
caused by HIV. More intervention trials are needed to assess
cognitive and neurological rehabilitation strategies and further
evaluate their benefit in PLWH.
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